↓ Skip to main content

Dove Medical Press

Article Metrics

The use of natalizumab for multiple sclerosis

Overview of attention for article published in Neuropsychiatric Disease and Treatment, June 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
4 news outlets
twitter
3 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
96 Mendeley
Title
The use of natalizumab for multiple sclerosis
Published in
Neuropsychiatric Disease and Treatment, June 2017
DOI 10.2147/ndt.s114636
Pubmed ID
Authors

Rachel Brandstadter, Ilana Katz Sand

Abstract

Natalizumab is a monoclonal antibody that acts as an α4 integrin antagonist to prevent leukocyte trafficking into the central nervous system. It is US Food and Drug Administration (FDA) approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Natalizumab demonstrated high efficacy in Phase III trials by reducing the annualized relapse rate, preventing multiple sclerosis (MS) lesion accumulation on magnetic resonance imaging, and decreasing the probability of sustained progression of disability. The leading safety concern with natalizumab is its association with progressive multifocal leukoencephalopathy (PML), a rare brain infection typically seen only in severely immunocompromised patients caused by reactivation of the John Cunningham virus (JCV). Careful analysis of risk factors for PML in natalizumab-treated MS patients, specifi-cally the presence of anti-JCV antibodies, has led to risk mitigation strategies to improve safety. Additional biomarkers are under investigation to further aid risk stratification. Natalizumab's high efficacy and favorable tolerability profile have led to a broad use by MS physicians, as both first-and second-line treatments. This review discusses the natalizumab efficacy, safety, and tolerability and finishes with pragmatic considerations regarding its use in clinical practice.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 96 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 25 26%
Student > Master 11 11%
Student > Ph. D. Student 9 9%
Researcher 8 8%
Student > Doctoral Student 5 5%
Other 15 16%
Unknown 23 24%
Readers by discipline Count As %
Medicine and Dentistry 25 26%
Biochemistry, Genetics and Molecular Biology 13 14%
Neuroscience 9 9%
Pharmacology, Toxicology and Pharmaceutical Science 7 7%
Immunology and Microbiology 7 7%
Other 10 10%
Unknown 25 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2019.
All research outputs
#643,534
of 15,771,386 outputs
Outputs from Neuropsychiatric Disease and Treatment
#74
of 2,564 outputs
Outputs of similar age
#19,341
of 269,371 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#3
of 89 outputs
Altmetric has tracked 15,771,386 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,564 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,371 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.